Drugs / Tuvusertib
Trials 16
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | EMD Serono Research & Development Institute, Inc. | Results Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment emdserono.com ↗
Data from DDRiver 301 Part B presented today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting show the ability to combine tuvusertib at a predicted efficacious dose with the PARP inhibitor niraparib |
| 2024-05-23 | EMD Serono Research & Development Institute, Inc. | Results EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024 emdserono.com ↗
Data show a manageable safety profile and preliminary efficacy in patients with advanced solid tumors, confirming suitability of this combination for further evaluation. |
| 2022-09-07 | EMD Serono Research & Development Institute, Inc. | Results EMD Serono to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients emdserono.com ↗
First-in-human results for potential best-in-class investigational ATR inhibitor M1774 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment emdserono.com ↗ |
| 2024-05-23 | EMD Serono Research & Development Institute, Inc. | EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024 emdserono.com ↗ |
| 2022-09-07 | EMD Serono Research & Development Institute, Inc. | EMD Serono to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients emdserono.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tuvusertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06433219 ↗ |
| Known as | M1774 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06518564 ↗ |
| Known as | MSC2584415A | “M1774 (substance code MSC2584415A; also known as VXc-400 or VRT-1363004) is an orally administered small molecule inhibitor of ATR kinase” NCT05986071 ↗ |
| Known as | VRT-1363004 | “M1774 (substance code MSC2584415A; also known as VXc-400 or VRT-1363004) is an orally administered small molecule inhibitor of ATR kinase” NCT05986071 ↗ |
| Known as | VXc-400 | “M1774 (substance code MSC2584415A; also known as VXc-400 or VRT-1363004) is an orally administered small molecule inhibitor of ATR kinase” NCT05986071 ↗ |
| Action | Inhibit | “ATR Inhibitor Tuvusertib” NCT05396833 ↗ |
| Modality | Small molecule | “M1774 (substance code MSC2584415A; also known as VXc-400 or VRT-1363004) is an orally administered small molecule inhibitor of ATR kinase” NCT05986071 ↗ |
| Route | Oral | “M1774 will be administered orally throughout the study.” NCT04170153 ↗ |
| Target | ATR | “ATR Inhibitor Tuvusertib” NCT05396833 ↗ |